JCERJournal of Contemporary Educational Research2208-84662208-8474Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcer.v9i3.9896ArticleConstruction of a New Clinical Teaching System for Non-Alcoholic Fatty Liver Disease (NAFLD) based on the Dynamic Training Model Integrating “Guidelines, Clinical Practice, and Scientific Research”https://artdesignp.com/journal/JCER/9/3/10.26689/jcer.v9i3.9896JiangSuzhen,WuNan2025932025-03-27With the shift in the definition of disease from non-alcoholic fatty liver disease (NAFLD) to metabolism-associated fatty liver disease (MAFLD), as well as the rapid evolution of pathological classification and therapeutic targets, traditional clinical teaching models face challenges such as outdated guideline updates, disjointed translation of scientific research, and limited skill training. This study proposes a dynamic training model integrating “guidelines, clinical practice, and scientific research.” Through stratified case-based teaching (e.g., FibroScan simulator and metabolic sand table), dynamic guideline analysis (comparing old and new evidence), and the integration of scientific thinking (visualization of CAND1 protein mechanism), a teaching system that integrates theory and practice is constructed. Innovatively developed smart assistant tools (AI decision support system, VR liver biopsy simulator) and a multi-dimensional evaluation system (deviation analysis of diagnosis and treatment pathways, milestone assessment) are used while emphasizing metabolic medicine integration (continuous glucose monitoring and digital therapy) and ethical privacy protection (federated learning framework). This model aims to cultivate students’ evidence-based decision-making skills and scientific research transformation thinking through dynamic knowledge base construction and interdisciplinary collaboration, providing sustainable teaching solutions to cope with the rapid iteration of NAFLD diagnosis and treatment.

Eslam M, Sanyal AJ, George J, 2020, MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. International Consensus Panel, 158(7): 1999–2014.

Gofton C, Upendran Y, Zheng M, et al., 2023, MAFLD: How is it Different from NAFLD? Clin Mol Hepatol, 29(Suppl): S17–S31.

Yip T, Lyu F, Lin H, et al., 2023, Non-invasive Biomarkers for Liver Inflammation in Non-alcoholic Fatty Liver Disease: Present and Future. Clin Mol Hepatol, 29(Suppl): S171–S183.

Huang X, Liu X, Li X, et al., 2023, Cullin-associated and Neddylation-Dissociated Protein 1 (CAND1) Alleviates NAFLD by Reducing Ubiquitinated Degradation of ACAA2. Nat Commun, 14(1): 4620.

Gong K, Wang M, Wang D, et al., 2023, Overexpression of NgBR Inhibits High-fat Diet-induced Atherosclerosis in ApoE-deficiency Mice. Hepatol Commun, 7(4): e0048.

Duseja A, Singh S P, De A, et al., 2023, Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). J Clin Exp Hepatol, 13(2): 273–302.

Boursier J, Mueller O, Barret M, et al., 2016, The Severity of Nonalcoholic Fatty Liver Disease is Associated with Gut Dysbiosis and Shift in the Metabolic Function of the Gut Microbiota. Hepatology, 63(3): 764–775.

Zhao Z, Wang Z, Zhou D, et al., 2021, Sodium Butyrate Supplementation Inhibits Hepatic Steatosis by Stimulating Liver Kinase B1 and Insulin-Induced Gene. Cellular and Molecular Gastroenterology and Hepatology, 12(3): 857–871.

Wang B, Sierad LN, Mercuri JJ, et al., 2022, Structural and Biomechanical Characterizations of Acellular Porcine Mitral Valve Scaffolds: Anterior Leaflets, Posterior Leaflets, and Chordae Tendineae. Eng Regen, 3(4): 374–386.

Ratziu V, Harrison SA, Hajji Y, et al., 2024, NIS2+TM as a Screening Tool to Optimize Patient Selection in Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials. J Hepatol, 80(2): 209–219.

Zhao G, Tian Z, Tian T, et al., 2021, TMBIM1 is an Inhibitor of Adipogenesis and its Depletion Promotes Adipocyte Hyperplasia and Improves Obesity-Related Metabolic Disease. Cell Metab, 33(8): 1640–1654.

Ni Y, Qian L, Siliceo S, et al., 2023, Resistant Starch Decreases Intrahepatic Triglycerides in Patients with NAFLD via gut Microbiome Alterations. Cell Metab, 35(9): 1530–1547.